Thursday, November 19, 2009
Print Current Session:
|
|
Thursday
SESSION XVII:
CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) IN NOVEMBER 2009 (5-MINUTE TALKS)
Moderators:Caron B. Rockman, MD / Anatoly V. Pokrovsky, MD
|
|
SESSION XVII SCHEDULE | |
2:28 PM - 2:33 PM | Debate 10: CAS Is Dead Based On Population Based Studies And Level I Evidence |
Presenters(s):Jean-Pierre Becquemin, MD, FRCS | |
2:34 PM - 2:39 PM | Debate 10: CAS Is Not Dead: It Will Have A Role In Symptomatic Patients When Used With New And Better Technology (Better Stents/Flow Reversal) And Better Patient Selection |
Presenters(s):Marc Bosiers, MD | |
2:40 PM - 2:45 PM | Anatomic And Lesion Characteristics Are Accurate Predictors Of Stroke From CAS: What Technique Is Best For Determining This? |
Presenters(s):Mark H. Wholey, MD | |
2:46 PM - 2:51 PM | New Key Information From The SPACE Trial: Cerebral Protection vs. No Cerebral Protection: Timing Of Strokes With CAS; Incidence Of Restenosis After CAS And CEA; Open vs. Closed Stents – Which Is Best? |
Presenters(s):Hans-Henning Eckstein, MD, PhD / Olav Jansen, MD | |
2:52 PM - 2:58 PM | Results Of The ICSS Trial: Randomized Comparison Of CAS vs. CEA In Symptomatic Patients |
Presenters(s):Frans L. Moll, MD, PhD | |
2:59 PM - 3:04 PM | 1-Year Results Of The CREST Trial: Randomized Comparison Of CAS vs. CEA In Symptomatic And Asymptomatic Patients |
Presenters(s):Wesley S. Moore, MD | |
3:05 PM - 3:10 PM | Where Do We Go From Here With Randomized Trials Of CAS vs. CEA: Do We Need More Trials In Asymptomatic Patients With A Best Medical Treatment Arm; More Trials With Better Patient Selection; Or More Trials With Better Technology For CAS (Flow Reversal and Better Stent Systems)? |
Presenters(s):Thomas Brott, MD | |
3:11 PM - 3:16 PM | CAS With Proximal Protection (Flow Cessation/Reversal) And Hybrid (Cristallo) Stents: Will This Be A Better And Universally Safe Approach? |
Presenters(s):Giancarlo Biamino, MD, PhD / Alberto Cremonesi, MD, FESC | |
3:17 PM - 3:22 PM | Debate 11: Indirect Markers Of Cerebral Embolization (TCD and Diffusion-Weighted MRI) Are Of Great Value In Differentiating Strategies For Embolic Protection In CAS |
Presenters(s):Sumaira Macdonald, MBChB (Comm), FRCP, FRCR, PhD | |
3:23 PM - 3:28 PM | Debate 11: Indirect Markers Of Cerebral Embolization (TCD and DW-MRI) Are Of Little Value In Differentiating Strategies For Embolic Protection In CAS Because Most Strokes With CAS Occur Before Or After Embolic Protection Devices Are Functioning |
Presenters(s):Emmanuel M. Houdart, MD | |
3:29 PM - 3:34 PM | Imaging Suite Of The Future Will Combine Many Modalities: What Can Be Combined With Fluoroscopy To Facilitate Endovascular Procedures? |
Presenters(s):Michael D. Dake, MD | |
3:35 PM - 3:40 PM | Panel Discussion |
Moderator(s): Mark H. Wholey, MD / Anatoly V. Pokrovsky, MD / Frank J. Veith, MD | |
3:40 PM - 3:45 PM | Debate 12: Medical Treatment Is Best For Most Asymptomatic Patients With Carotid Stenosis |
Presenters(s):Peter R.F. Bell, MD, FRCS, DSC, KBE | |
3:46 PM - 3:51 PM | Debate 12: CEA Or CAS, Not Medical Treatment, Is Best For Most Asymptomatic Patients With >60% Carotid Stenosis |
Presenters(s):Peter A. Schneider, MD | |
3:52 PM - 3:57 PM | Interventional Treatment (CAS or CEA) Should Await New Diagnostic Methods: What Is On The Horizon? |
Presenters(s):Henrik Sillesen, MD, DMSc | |
3:58 PM - 4:03 PM | Best Medical Treatment Is Currently The Optimal Management For >60% Carotid Stenosis In Asymptomatic Patients: What Is Needed To Maximize The Benefit Of CAS In Such Patients? |
Presenters(s):Michael R. Jaff, DO | |
4:04 PM - 4:09 PM | Value Of Intense Lipid Lowering Treatment In Patients With Asymptomatic Carotid Stenosis |
Presenters(s):J. David Spence, MD | |
4:10 PM - 4:15 PM | How To Identify Vulnerable Carotid Plaques In Asymptomatic Patients Noninvasively With Molecular Imaging |
Presenters(s):Clark J. Zeebregts, MD, PhD | |
4:16 PM - 4:21 PM | How To Predict Which Asymptomatic Patients Are At High Risk For Stroke So They Can Be Treated Invasively Without Treating All Asymptomatic Patients: Present Status And Future Possibilities |
Presenters(s):Giorgio M. Biasi, MD | |
4:22 PM - 4:27 PM | Effect Of Exercise And Statins On Carotid Plaques: Implications For Invasive Treatment Of Asymptomatic Patients |
Presenters(s):Christos D. Liapis, MD | |
4:28 PM - 4:33 PM | Status Of The TACIT Trial: Will We Ever Know The Truth About How Asymptomatic Patients With Carotid Stenosis Should Be Treated?: Will The Stimulus Package Save The Day For TACIT? |
Presenters(s):John H. Rundback, MD, FSIR, FAHA | |
4:34 PM - 4:39 PM | Panel Discussion |
END OF SESSION XVII | |
previous | next |